Legacy
“Legacy Novozymes has leveraged its strengths of a well-diversified portfolio, unique production capabilities, and broad market presence to deliver strong growth in a volatile market. Biosolutions hold the key to some of the world’s biggest challenges, and the growth in 2023 confirms the continued trajectory to growth as well as demand and strong momentum, says Ester Baiget, President & CEO, and continues:
“Now, we start a new chapter as Novonesis. The combination between two great companies is now a reality, and we are set to further accelerate growth and to develop transformative biosolutions as the leading global biosolutions partner. We have gathered the brightest minds, and together with my more than 10,000 colleagues, we will unlock the limitless potential of biosolutions. A special thank you to all our stakeholders for your support. We are ready to lead the new era of biosolutions.”
In the 2023 financial year, legacy
Growth rates across business areas
For the full year, organic performance by business area was 5% in Household Care, -2% in Food,
Performance in Food,
Strong growth across both developed and emerging markets
Legacy
Bioenergy was the main driver of growth in developed markets with contributions from Agriculture,
Growth in emerging markets was driven by Bioenergy and with contributions from Household Care.
For 2023, organic growth rates by geography were 3% in
-1% in
Media Relations | ||
Lina Danstrup Head of Phone: +45 30 77 05 52 anse@novozymes.com | ||
Investor Relations | ||
Tobias Cornelius Björklund Head of Investor Relations Phone: +45 30 77 86 82 tobb@novozymes.com |
[*] Special items include costs related to the combination with Chr. Hansen
Attachment
- Novozymes FY_2023_Press Release
© OMX, source